This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Ezetrol, Zient, Absorcol, ezetimibe, SCH 58235
Description: Zetia (ezetimibe) lowers cholesterol by localizing at the brush border of the small intestine to inhibit cholesterol absorption. This mechanism of action makes Zetia complementary to statins, which work by inhibiting cholesterol synthesis in the liver.
Zetia is metabolized to an active glucuronide metabolite, which is even more potent. Repeated enterohepatic circulation of the metabolite leads to a long duration of action.
The specific molecular target for Zetia is thought to be Niemann–Pick C1-Like 1 (NPC1L1), a protein critical for cholesterol absorption.
Revenue splits for this drug are BioMedTracker estimates.
Merck/Schering-Plough Pharmaceuticals is a joint venture between Merck & Co., Inc. and Schering-Plough Corporation formed in May 2000 to develop and market in the United States new prescription medicines in cholesterol management. The collaboration was expanded in Dec. 2001 to include worldwide markets (excluding Japan).
The agreement provides for the sharing of net income/(loss) based upon percentages that vary by product, sales level and country. In the U.S. market, Schering receives a greater share of profits on the first $300 million of annual Zetia sales. Above $300 million of annual Zetia sales, Merck and Schering share profits equally. Either Partners share of the joint ventures net income/(loss) is subject to a reduction if the Partner fails to perform a specified minimum number of physician details in a particular country. The Partners agree annually to the minimum number of physician details by...See full deal structure in Biomedtracker
Partners: Bayer AG Laboratorios Farmacéuticos Rovi, S.A.
Additional information available to subscribers only: